ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Conditions: Pancreatic Ductal Carcinoma
Interventions: Drug: ProAgio Dose Levels (DL) 1,2,3,4; Drug: Gemcitabine, nab paclitaxel
Sponsors: ProDa BioTech, LLC; University of Alabama at Birmingham; Georgia State University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 26, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments